...which are going off patent in the coming years. However, this problem is not insurmountable; the company has a diabetes drug, Lantus , Multaq for irregular heartbeats, the world's leading vaccine division and strong potential in cancer...

In this article: Jim Cramer, Lear, Sanofi-Aventis, J.Crew, Bankruptcy, FRO, Magna International, Gentex, and Hewlett Packard

...diabetes who cannot control their condition effectively with a combination of diet, physical activity and insulin. Sitagliptin is a once-daily DPP-4 inhibitor that works by blocking the action of DPP-4, an enzyme which destroys the hormone...

In this article: Sitagliptin, Insulin, Type 2 diabetes, Incretin, Liver, Metformin, Dpp-4 Inhibitor, Hormone, and Glucose

...conducted in various sites for Type 2 patients. The results for the first time speak of the commercial appeal oral insulin may bring to insulin dependent diabetics. This is an example of the Type 2 market that has eluded the major insulin...

In this article: Insulin, FDA, Glucose, Novo Nordisk, Phase IV, Sanofi-Aventis, and Hyperglycemia

...7.8% of the population, who have the disease. Diabetes is a chronic disease in which the body does not produce or properly use insulin. Insulin is a hormone that is needed to convert sugars and other nutrients into glucose , which is the...

In this article: Sglt2, Sugar, Dapagliflozin, Diabetes, HbA1c, Glucose, Obesity, and Insulin

...was strong. Sales grew 8%, including favorable exchange rate effects from the euro, while emerging-market sales rose 21%. Sanofi 's drugs Lantus , Lovenox, and Plavix , which it sells with Bristol-Myers Squibb ( NYSE : BMY ), performed well,...

In this article: Sanofi-Aventis, NYSE, Regeneron, Novartis AG, Berkshire Hathaway, Eli Lilly, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline

... TEVA Early last year, the FDA approved a new drug in the fight against adult-onset, type II diabetes, Glumetza. Glumetza is a new form of Metformin , a generic drug with many problems in uptake and gastric side-effects. Glumetza is a...

In this article: Metformin, TEVA, FDA, Sugar, Ivax, BMY, US, Credit crunch, and Insulin

...lifestyle intervention" (basically, changing diet and exercise habits) was more powerful that the commonly prescribed drug treatment with metformin. In the early stages, the lifestyle effect reduced the incidence of diabetes by 58%, compared...

In this article: Obesity, Insulin, Diabetes mellitus, Type 1 diabetes, Niddm, Edinburgh University, Metformin, Cancer, and The Lancet

...two Amylin drugs in mid-stage trials. Takeda, Japan 's biggest drugmaker and best known for its diabetes drug Actos , will pay Amylin $75 million in a one-time up-front payment under the exclusive worldwide agreement. Amylin , maker of...

In this article: Amylin, Obesity, Takeda Pharmaceutical, United States, Pramlintide, Actos, Byetta, and Japan

...to co-develop obesity drugs * Amylin to receive $75 mln up-front * Milestone payments to Amylin could top $1bln * Includes two Amylin drugs in Phase II trials (Adds details) Japan 's Takeda Pharmaceutical <4502. T> and U.S....

In this article: Amylin, Obesity, United States, Pramlintide, Actos, Byetta, Takeda Pharmaceutical, and Japan

...earnings calls to the afternoon Paris time. When the drug safety police this year linked Lantus , the company 's $4-billion-a-year long-acting insulin , to cancer , he responded quickly, assembling a committee of experts on diabetes and tumors to...

In this article: Sanofi, Bristol-Myers Squibb, Pfizer, Cancer, Breast cancer, Sanofi-Synthelabo, Novartis, and Glaxo

...making way for cheaper copies from generic drugmakers. Third-quarter sales growth, pulled by anti-thrombosis drug Lovenox, insulin Lantus , as well as vaccines, was partly held back by competition from generics to Sanofi 's cancer drug...

In this article: Sanofi-Aventis, Revenue, Eloxatin, Lantus, European Union, United States, Plavix, and Cancer

...its third-quarter net income rose 6%, buoyed by a strong performance in emerging markets and a surge in global sales of the Lantus insulin drug. The Paris -based company also raised its full-year guidance, citing an expected fourth-quarter...

In this article: Sanofi-Aventis, Lantus, Amortization, Insulin, Paris, Intangible asset, Revenue, Tax, and Actonel

...8.0% to 7.4 billion euros. Exchange rate movements had a favorable effect of 2.0 percentage points, the firm said. Sales insulin drug Lantus rose 27.1% to 778 million euros in the quarter, while Plavix sales rose 5.6% to 664 million euros.

In this article: Sanofi-Aventis, Amortization, Intangible asset, Tax, Actonel, Eloxatin, Lantus, Plavix, Insulin, and Nasacort

...intervention in the DPP, all three groups were offered group-implemented lifestyle intervention. Metformin treatment was continued in the original metformin group (850 mg twice daily as tolerated), and the original lifestyle intervention group...

In this article: Metformin, Diabetes, Medical advice, American Diabetes Association, Peptide, Metabolic syndrome, Metabolic Diseases, and The Lancet

...up to 20 mg once weekly after 4 weeks. Four of the eight studies have active comparators, including exenatide , sitagliptin , insulin glargine and pioglitazone. Taspoglutide was selected from a family of human once-weekly long-acting...

In this article: Exenatide, Glp-1, Thiazolidinedione, HbA1c, Diabetes mellitus, Metformin, Insulin, Hormone, and Sitagliptin

...with partner AstraZeneca PLC. It was approved for sale in the European Union 's 27 countries two weeks ago. The drug is part of the DPP-4 inhibitor class of diabetes drugs, so it competes with Merck & Co.'s popular Januvia. In...

In this article: Bristol-Myers, Plavix, Revenue, Abilify, Food and Drug Administration, AstraZeneca PLC, Bristol, Ipilimumab, and Otsuka Pharmaceutical Co.

...better efficacy but worse safety than the Phase III results presented in Vienna , where dapagliflozin was tested in combination with the older drug metformin. Baum continues to see a 50 percent chance of the drug being launched in 2011...

In this article: Dapagliflozin, Vienna, Arizona, Metformin, HbA1c, Glucose, Sglt2, Bristol-Myers Squibb, and Morgan Stanley

Article Date: 10 Oct 2009 - 6:00 PDT Phase III trial results with Boehringer Ingelheim's DPP-4 inhibitor linagliptin confirm the favourable efficacy and safety profile seen in investigational studies, according to reports at a briefing...

In this article: Glucose, Linagliptin, Dpp-4 Inhibitor, HbA1c, Medical advice, and Cardiovascular disease